Treatment effects of oxaliplatin combined with gemcitabine on colorectal cancer and its influence on HMGB1 expression

about

Treatment effects of oxaliplatin combined with gemcitabine on colorectal cancer and its influence on HMGB1 expression

Item

http://www.wikidata.org/entity/Q42134391

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Treatment effects of oxaliplat ...... influence on HMGB1 expression

@en

Treatment effects of oxaliplat ...... influence on HMGB1 expression

@nl

type

Item

label

Treatment effects of oxaliplat ...... influence on HMGB1 expression

@en

Treatment effects of oxaliplat ...... influence on HMGB1 expression

@nl

prefLabel

Treatment effects of oxaliplat ...... influence on HMGB1 expression

@en

Treatment effects of oxaliplat ...... influence on HMGB1 expression

@nl

P1476

Treatment effects of oxaliplat ...... influence on HMGB1 expression

@en

P2093

Lin Jiang

http://www.w3.org/2001/XMLSchema#string

Shuangshuang Wen

http://www.w3.org/2001/XMLSchema#string

Xiaopeng Du

http://www.w3.org/2001/XMLSchema#string

Yanyan Gou

http://www.w3.org/2001/XMLSchema#string

P2860

HMGB1 and RAGE in inflammation and cancer

Cancer statistics, 2007

High-mobility group box 1 and cancer.

Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine.

Gemcitabine plus S-1 versus cetuximab as a third-line therapy in metastatic colorectal cancer: an observational trial.

HMGB proteins: interactions with DNA and chromatin.

Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma.

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.

High mobility group box-1 is phosphorylated by protein kinase C zeta and secreted in colon cancer cells.

Serum Type IV Collagen Concentration Correlates with Indocyanine Green Retention Rate and is an Indicator Of Hepatotoxicity In Patients Receiving FOLFOX for Colorectal Cancer.

P304

3187-3190

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2016.5053

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27899980

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5103918

http://www.w3.org/2001/XMLSchema#string